newsfilter
← Latest News
Business Wire·

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Genmab A/S (NASDAQ:GMAB) and Incyte (NASDAQ:INCY)